Pheochromocytoma: all 151 studies
Page 2 of 2. Open to participants first (56), then studies with results posted, then the rest; newest registration first within each.
- the Effect of Dexmedetomidine and Magnesium Sulfate in Open Resection of PheochromocytomaCompletedNCT04320589Phase 2
- Phase-II Study of Lu177DOTATOC in Adults With STTR(+)Pulmonary, Pheochromocytoma, Paraganglioma, Unknown Primary, Thymus NETs (PUTNET), or Any Other Non-.GEP-NET.WithdrawnNCT04276597Phase 2
- Radioactive Drug (177Lu-DOTATATE) for the Treatment of Locally Advanced, Metastatic, or Unresectable Rare Endocrine CancersWithdrawnNCT04106843Phase 2
- Prevention of Conversion in Posterior Retroperitoneal Adrenalectomy by Measuring Preoperative Anatomical ConditionsCompletedNCT04071561
- The Registry of Oncology Outcomes Associated with Testing and TreatmentCompletedNCT04028479
- Cryoablation of Bone Metastases From Endocrine TumorsTerminatedNCT03986593Not applicable
- LAnreotide in Metastatic Pheochromocytoma / PARAganglioma (LAMPARA)Active, not recruitingNCT03946527Phase 2
- Dosimetry Guided PRRT With 177Lu-DOTATATE in Children and AdolescentsWithdrawnNCT03923257Phase 1/2
- Study of Axitinib (AG-013736) With Evaluation of the VEGF-pathway in Pheochromocytoma/ParagangliomaActive, not recruitingNCT03839498Phase 2
- 131I-Metaiodobenzylguanidine (131I-MIBG) Therapy for Relapsed/Refractory NeuroblastomaNo longer availableNCT03649438
- DOTATOC PET/CT for Imaging NET PatientsActive, not recruitingNCT03583528
- 18F-Fluorodopamine PET Studies of Neuroblastoma and PheochromocytomaActive, not recruitingNCT03541720Early Phase 1
- Surgeon-Anesthesiologist CollaborationStatus unknownNCT03158870
- Expanded Access Program of Ultratrace Iobenguane I131 for Malignant Relapsed/Refractory Pheochromocytoma/ParagangliomaApproved for marketingNCT02961491
- Nivolumab and Ipilimumab in Treating Patients With Rare TumorsActive, not recruitingNCT02834013Phase 2
- Veliparib, Capecitabine, and Temozolomide in Patients With Advanced, Metastatic, and Recurrent Neuroendocrine TumorWithdrawnNCT02831179Phase 1
- Efficacy and Safety of Posterior Retroperitoneoscopic Adrenalectomy: A Comparative StudyCompletedNCT02618694Not applicable
- Effect of Cabozantinib S-Malate or Lenvatinib Mesylate on Weight and Body Composition in Patients With Metastatic Endocrine CancerCompletedNCT02592356Not applicable
- 18F-FDOPA PET in Neuroendocrine TumoursNo longer availableNCT02431715
- Comparison of Diagnostic Performances of 68Ga-DOTATATE PET-CT and 18F-FDOPA PET-CT in Paragangliomas and Pheochromocytomas EvaluationCompletedNCT02186678Not applicable
- Randomized Clinical Trial of Posterior Retroperitoneoscopic Adrenalectomy Versus Lateral Laparoscopic AdrenalectomyCompletedNCT01959711Phase 4
- Effect of Chronic Catecholamine Overproduction on Brown Adipose TissueCompletedNCT01949714
- Phase I Trial of Vandetanib Combined With 131I-mIBG to Treat Patients With Advanced Phaeochromocytoma and ParagangliomaWithdrawnNCT01941849Phase 1
- MIBG for Refractory Neuroblastoma and PheochromocytomaCompletedNCT01850888Not applicable
- Expanded Access Protocol Using 131I-MIBG Therapy +/- Vorinostat for Refractory Neuroblastoma, Pheochromocytoma, or ParagangliomaNo longer availableNCT01838187
- Natural History Study of Children and Adults With Medullary Thyroid CancerActive, not recruitingNCT01660984
- Dovitinib in Neuroendocrine TumorsCompletedNCT01635907Phase 2
- Non-invasive Evaluation of Fluid Status and Cardiac Output During Operative Treatment of PheochromcytomaCompletedNCT01425710
- Phenoxybenzamine Versus Doxazosin in PCC PatientsCompletedNCT01379898Phase 4
- Compassionate Use of 131I-MIBG for Patients With Malignant PheochromocytomaApproved for marketingNCT01377532
- 123I-MIBG Scintigraphy in Patients Being Evaluated for Neuroendocrine TumorsStatus unknownNCT01373736Phase 3
- First International Randomized Study in Malignant Progressive Pheochromocytoma and ParagangliomaCompletedNCT01371201Phase 2
- Temsirolimus and Vinorelbine Ditartrate in Treating Patients With Unresectable or Metastatic Solid TumorsCompletedNCT01155258Phase 1
- RAD001 in Pheochromocytoma or Nonfunctioning CarcinoidCompletedNCT01152827Phase 2
- Specificity of Elevated Plasma EM66 Levels in PheochromocytomaCompletedNCT01022515Not applicable
- Visualizing Vascular Endothelial Growth Factor (VEGF) Producing Lesions in Von Hippel-Lindau DiseaseCompletedNCT00970970
- Content Validation of Quality of Life and Symptom Questionnaires for Pheochromocytoma and ParagangliomaTerminatedNCT00911729
- Everolimus and Vatalanib in Treating Patients With Advanced Solid TumorsCompletedNCT00655655Phase 1
- I-123-MIBG for Imaging of Neuroblastoma and PheochromocytomaCompletedNCT00590096
- Internal Radiation Therapy in Treating Patients With Liver Metastases From Neuroendocrine TumorsTerminatedNCT00466856Phase 2
- ULTRATRACE Iobenguane I 131 in Patients With Malignant Pheochromocytoma, Paraganglioma, or Metastatic CarcinoidCompletedNCT00339131Phase 1
- Hereditary Paraganglioma: Evaluation of Screening Methods to Detect Tumors in SDH Positive CarriersCompletedNCT00188019Not applicable
- Meta-Iodobenzylguanidine (123I mIBG) Scintigraphy in Patients Being Evaluated for Phaeochromocytoma or NeuroblastomaCompletedNCT00126412Phase 3
- Radiolabeled Octreotide in Treating Children With Advanced or Refractory Solid TumorsCompletedNCT00049023Phase 1
- 131MIBG to Treat Malignant PheochromocytomaCompletedNCT00028106Phase 2
- Indium In 111 Pentetreotide in Treating Patients With Refractory CancerTerminatedNCT00002947Phase 1
- Surgery With or Without Combination Chemotherapy in Treating Patients With Lung Metastases From Soft Tissue SarcomaCompletedNCT00002764Phase 3
- Surgery With or Without Chemotherapy in Treating Patients With Soft Tissue SarcomaCompletedNCT00002641Phase 3
- Combination Chemotherapy and Tamoxifen in Treating Patients With Solid TumorsCompletedNCT00002608Phase 2
- Diagnosis and Treatment of PheochromocytomaCompletedNCT00001229
- Blood Sampling for Neurochemical and Genetic TestingCompletedNCT00001147